Detalhe da pesquisa
1.
A phase 3 randomized, open-label, multicenter trial for safety and efficacy of combined trabectedin and pegylated liposomal doxorubicin therapy for recurrent ovarian cancer.
Gynecol Oncol
; 156(3): 535-544, 2020 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-31924332
2.
Safety and efficacy of trabectedin when administered in the inpatient versus outpatient setting: Clinical considerations for outpatient administration of trabectedin.
Cancer
; 125(24): 4435-4441, 2019 Dec 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-31503332
3.
Prognostic Value of Fibroblast Growth Factor Receptor Genetic Alterations in Metastatic Urothelial Carcinoma.
Clin Genitourin Cancer
; 22(3): 102054, 2024 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-38457853
4.
Cardiac safety of trabectedin monotherapy or in combination with pegylated liposomal doxorubicin in patients with sarcomas and ovarian cancer.
Cancer Med
; 10(11): 3565-3574, 2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-33960681
5.
Data on prior pegylated liposomal doxorubicin (PLD) treatment in recurrent ovarian cancer: Post-hoc data analysis from the phase 3 randomized, open-label study comparing trabectedin and PLD versus PLD alone in patients with recurrent ovarian cancer.
Data Brief
; 30: 105465, 2020 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-32346557
6.
Development and usability of a new subcutaneous auto-injector device to administer hydroxyprogesterone caproate to reduce the risk of recurrent preterm birth.
Med Devices (Auckl)
; 11: 241-252, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-30100767
7.
Development of novel substrates for tumor immunotherapy.
J Control Release
; 91(1-2): 209-24, 2003 Aug 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-12932653
8.
Absorbable microparticulate cation exchanger for immunotherapeutic delivery.
J Biomed Mater Res B Appl Biomater
; 69(2): 173-82, 2004 May 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-15116407
9.
Injectable in situ forming controlled release implant composed of a poly-ether-ester-carbonate and applications in the field of chemotherapy.
J Biomed Mater Res A
; 100(9): 2365-72, 2012 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-22528373
10.
A cell-based artificial antigen-presenting cell coated with anti-CD3 and CD28 antibodies enables rapid expansion and long-term growth of CD4 T lymphocytes.
Clin Immunol
; 105(3): 259-72, 2002 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-12498807